FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149267166> ?p ?o ?g. }

• W2149267166 endingPage "217" @default.
• W2149267166 startingPage "209" @default.
• W2149267166 abstract "Patupilone is a novel microtubule-targeting cytotoxic agent, which exerts its antitumor effect through microtubule stabilization. Pharmacokinetics, pharmacodynamics, and safety of warfarin when administered concomitantly with patupilone were investigated, and antitumor activity was assessed. This was a phase I, two-center, drug-drug interaction study. In the core phase of the study, treatment consisted of warfarin 20 mg orally (days 1 and 29) and patupilone 10 mg/m(2) i.v. (days 8 and 29). Patients benefiting from patupilone treatment continued treatment every 3 weeks (extension phase) until progression of disease, death, or unacceptable toxicity. Seventeen patients were treated (core phase, 17; extension, 9). The geometric mean ratios (comedication/monotherapy) for C(max) and area under the curve(0-168) of warfarin were near unity and their 90% confidence intervals were within the equivalence limits of 0.80 and 1.25. The half-life, plasma clearance, and International Normalized Ratio (INR) of warfarin were not affected by patupilone coadministration. The most common adverse events were diarrhea, nausea, vomiting, abdominal pain, anorexia, dehydration, asthenia, and peripheral neuropathy. Five (29.4%) patients experienced grade 3 study drug-related adverse events (diarrhea, 17.6%; increased INR, 11.8%; dehydration, 5.9%; and neutropenia, 5.9%). One patient with triple-negative breast cancer (estrogen receptor, progesterone receptor, and HER2/neu negative) had a partial response (35% decrease in tumor measurements by Response Evaluation Criteria in Solid Tumors), and 11 had stable disease for 6 weeks or more (≥12 weeks, 6 patients). The pharmacokinetics and pharmacodynamics of warfarin were not affected by patupilone coadministration, suggesting that patupilone has no clinically relevant effect on CYP2C9 metabolism. Patupilone showed antitumor activity in triple-negative breast cancer." @default.
• W2149267166 created "2016-06-24" @default.
• W2149267166 creator A5000961519 @default.
• W2149267166 creator A5014122300 @default.
• W2149267166 creator A5028833538 @default.
• W2149267166 creator A5033917876 @default.
• W2149267166 creator A5042271475 @default.
• W2149267166 creator A5044840107 @default.
• W2149267166 creator A5045286901 @default.
• W2149267166 creator A5052731379 @default.
• W2149267166 creator A5053481267 @default.
• W2149267166 creator A5070781484 @default.
• W2149267166 creator A5087024085 @default.
• W2149267166 date "2011-01-01" @default.
• W2149267166 modified "2023-09-25" @default.
• W2149267166 title "Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Advanced Malignancies: A Phase I Clinical Trial" @default.
• W2149267166 cites W2003278673 @default.
• W2149267166 cites W2045824232 @default.
• W2149267166 cites W2047815869 @default.
• W2149267166 cites W2053857197 @default.
• W2149267166 cites W2068634821 @default.
• W2149267166 cites W2075677078 @default.
• W2149267166 cites W2099243119 @default.
• W2149267166 cites W2104966951 @default.
• W2149267166 cites W2139248078 @default.
• W2149267166 cites W2139994556 @default.
• W2149267166 cites W2147070133 @default.
• W2149267166 cites W2154812064 @default.
• W2149267166 cites W2156320702 @default.
• W2149267166 cites W2243567906 @default.
• W2149267166 cites W2248393455 @default.
• W2149267166 cites W2275070547 @default.
• W2149267166 cites W30895175 @default.
• W2149267166 cites W2147051864 @default.
• W2149267166 doi "https://doi.org/10.1158/1535-7163.mct-10-0774" @default.
• W2149267166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21220503" @default.
• W2149267166 hasPublicationYear "2011" @default.
• W2149267166 type Work @default.
• W2149267166 sameAs 2149267166 @default.
• W2149267166 citedByCount "7" @default.
• W2149267166 countsByYear W21492671662012 @default.
• W2149267166 countsByYear W21492671662014 @default.
• W2149267166 countsByYear W21492671662017 @default.
• W2149267166 countsByYear W21492671662019 @default.
• W2149267166 crossrefType "journal-article" @default.
• W2149267166 hasAuthorship W2149267166A5000961519 @default.
• W2149267166 hasAuthorship W2149267166A5014122300 @default.
• W2149267166 hasAuthorship W2149267166A5028833538 @default.
• W2149267166 hasAuthorship W2149267166A5033917876 @default.
• W2149267166 hasAuthorship W2149267166A5042271475 @default.
• W2149267166 hasAuthorship W2149267166A5044840107 @default.
• W2149267166 hasAuthorship W2149267166A5045286901 @default.
• W2149267166 hasAuthorship W2149267166A5052731379 @default.
• W2149267166 hasAuthorship W2149267166A5053481267 @default.
• W2149267166 hasAuthorship W2149267166A5070781484 @default.
• W2149267166 hasAuthorship W2149267166A5087024085 @default.
• W2149267166 hasConcept C111113717 @default.
• W2149267166 hasConcept C112705442 @default.
• W2149267166 hasConcept C126322002 @default.
• W2149267166 hasConcept C197934379 @default.
• W2149267166 hasConcept C2776301958 @default.
• W2149267166 hasConcept C2779161974 @default.
• W2149267166 hasConcept C2780580376 @default.
• W2149267166 hasConcept C2780852908 @default.
• W2149267166 hasConcept C71924100 @default.
• W2149267166 hasConcept C76318530 @default.
• W2149267166 hasConcept C90924648 @default.
• W2149267166 hasConcept C98274493 @default.
• W2149267166 hasConceptScore W2149267166C111113717 @default.
• W2149267166 hasConceptScore W2149267166C112705442 @default.
• W2149267166 hasConceptScore W2149267166C126322002 @default.
• W2149267166 hasConceptScore W2149267166C197934379 @default.
• W2149267166 hasConceptScore W2149267166C2776301958 @default.
• W2149267166 hasConceptScore W2149267166C2779161974 @default.
• W2149267166 hasConceptScore W2149267166C2780580376 @default.
• W2149267166 hasConceptScore W2149267166C2780852908 @default.
• W2149267166 hasConceptScore W2149267166C71924100 @default.
• W2149267166 hasConceptScore W2149267166C76318530 @default.
• W2149267166 hasConceptScore W2149267166C90924648 @default.
• W2149267166 hasConceptScore W2149267166C98274493 @default.
• W2149267166 hasIssue "1" @default.
• W2149267166 hasLocation W21492671661 @default.
• W2149267166 hasLocation W21492671662 @default.
• W2149267166 hasOpenAccess W2149267166 @default.
• W2149267166 hasPrimaryLocation W21492671661 @default.
• W2149267166 hasRelatedWork W1973811753 @default.
• W2149267166 hasRelatedWork W2041128529 @default.
• W2149267166 hasRelatedWork W2066320494 @default.
• W2149267166 hasRelatedWork W2142080078 @default.
• W2149267166 hasRelatedWork W2227061539 @default.
• W2149267166 hasRelatedWork W2358248846 @default.
• W2149267166 hasRelatedWork W243857094 @default.
• W2149267166 hasRelatedWork W2974708347 @default.
• W2149267166 hasRelatedWork W3125789345 @default.
• W2149267166 hasRelatedWork W4285393230 @default.
• W2149267166 hasVolume "10" @default.
• W2149267166 isParatext "false" @default.
• W2149267166 isRetracted "false" @default.

• next